These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30055223)

  • 41. A review of Formulations of Commercially Available Antibodies.
    Strickley RG; Lambert WJ
    J Pharm Sci; 2021 Jul; 110(7):2590-2608.e56. PubMed ID: 33789155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid Polysorbate 80 Degradation by Liver Carboxylesterase in a Monoclonal Antibody Formulated Drug Substance at Early Stage Development.
    Zhang S; Xiao H; Molden R; Qiu H; Li N
    J Pharm Sci; 2020 Nov; 109(11):3300-3307. PubMed ID: 32721471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stabilizing Polysorbate 20 and 80 Against Oxidative Degradation.
    Schmidt A; Koulov A; Huwyler J; Mahler HC; Jahn M
    J Pharm Sci; 2020 Jun; 109(6):1924-1932. PubMed ID: 32171713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of histopathological findings at the injection site following degarelix administration.
    Maeda T; Kosaka T; Honda A; Okata U; Hayakawa N; Ito Y; Nagata H; Chen KR; Nakamura S; Oya M
    Support Care Cancer; 2015 May; 23(5):1377-81. PubMed ID: 25358643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80.
    Badiu I; Geuna M; Heffler E; Rolla G
    BMJ Case Rep; 2012 May; 2012():. PubMed ID: 22605841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
    Shear NH; Paul C; Blauvelt A; Gooderham M; Leonardi C; Reich K; Ohtsuki M; Pangallo B; Xu W; Ball S; Ridenour T; Torisu-Itakura H; Agada N; Mallbris L
    J Drugs Dermatol; 2018 Feb; 17(2):200-206. PubMed ID: 29462229
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On-line coupling of hydrophobic interaction column with reverse phase column -charged aerosol detector/mass spectrometer to characterize polysorbates in therapeutic protein formulations.
    He Y; Brown P; Bailey Piatchek MR; Carroll JA; Jones MT
    J Chromatogr A; 2019 Feb; 1586():72-81. PubMed ID: 30551943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric Safety of Polysorbates in Drug Formulations.
    Kriegel C; Festag M; Kishore RSK; Roethlisberger D; Schmitt G
    Children (Basel); 2019 Dec; 7(1):. PubMed ID: 31877624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.
    Schiefelbein L; Keller M; Weissmann F; Luber M; Bracher F; Friess W
    Eur J Pharm Biopharm; 2010 Nov; 76(3):342-50. PubMed ID: 20816956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro testing of tensides employing monolayer cultures: a comparison with results of patch tests on human volunteers.
    Benassi L; Bertazzoni G; Seidenari S
    Contact Dermatitis; 1999 Jan; 40(1):38-44. PubMed ID: 9928803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surface activity of a monoclonal antibody.
    Mahler HC; Senner F; Maeder K; Mueller R
    J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations.
    Calogiuri G; Garvey LH; Romita P; Macchia L; Foti C
    Antiinflamm Antiallergy Agents Med Chem; 2016; 15(2):91-100. PubMed ID: 27834127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biologic-induced urticaria due to polysorbate 80: usefulness of prick test.
    Pérez-Pérez L; García-Gavín J; Piñeiro B; Zulaica A
    Br J Dermatol; 2011 May; 164(5):1119-20. PubMed ID: 21219296
    [No Abstract]   [Full Text] [Related]  

  • 54. Parenteral nutrition hypersensitivity.
    Levy M; Dupuis LL
    JPEN J Parenter Enteral Nutr; 1990; 14(2):213-5. PubMed ID: 2112631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Degradation of polysorbates 20 and 80 catalysed by histidine chloride buffer.
    Brovč EV; Mravljak J; Šink R; Pajk S
    Eur J Pharm Biopharm; 2020 Sep; 154():236-245. PubMed ID: 32693155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates.
    Castañeda Ruiz AJ; Shetab Boushehri MA; Phan T; Carle S; Garidel P; Buske J; Lamprecht A
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559072
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The unusual suspects: a surprise regarding reactions to omalizumab.
    Lieberman P
    Allergy Asthma Proc; 2007; 28(3):259-61. PubMed ID: 17619552
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy.
    Singh SM; Bandi S; Jones DNM; Mallela KMG
    J Pharm Sci; 2017 Dec; 106(12):3486-3498. PubMed ID: 28843351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High volume of polysorbate-containing (Tween
    Wagner N; Podda M
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1972-1976. PubMed ID: 29633392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the Local Tolerability to 5 Long-acting Drug Nanosuspensions with Different Stabilizing Excipients, Following a Single Intramuscular Administration in the Rat.
    Chamanza R; Darville N; van Heerden M; De Jonghe S
    Toxicol Pathol; 2018 Jan; 46(1):85-100. PubMed ID: 29096596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.